Clinical Trials
3 trialsNCT06829355 2025-02-17
THYMI
Beijing Friendship Hospital
Phase 2 Recruiting
NCT02906150 2016-09-19
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type
SciClone Pharmaceuticals
Phase 2 Unknown
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown